Cambridge, MA-based biotech Genzyme, now a unit of Sanofi-Aventis (NYSE:[[ticker:SNY]]), has amended its patent infringement lawsuit against its competitor Anika Therapeutics (NASDAQ:[[ticker:ANIK]]) related to Anika’s osteoarthritis treatment, Monovisc. Genzyme also filed a new complaint in U.S. District Court in Boston that includes a newly issued patent, according to Anika. Genzyme, the world’s largest maker of rare disease drugs, makes a product for knee joint pain from osteoarthritis called Synvisc-One that competes with Anika’s Monovisc. Both products are single injections of hyaluronic acid-based treatments. Bedford, MA-based Anika said in a statement yesterday that it plans to “vigorously defend the lawsuits and the Monovisc franchise.”
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
